Actively Recruiting
Phase 1 Study of Oral INCB123667 in Adults With Severe Renal Impairment or End Stage Renal Disease Evaluating Safety and How the Body Processes the Drug
Led by Incyte Corporation · Updated on 2026-06-16
16
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying the safety and how the body processes the drug INCB123667 when taken orally by adults with severe kidney problems or those with end stage renal disease. This Phase 1 study aims to understand the drugs behavior in these two groups to help guide future treatments. Participants are adults aged 18 to 85 years with significant kidney impairment. The study has two groups Group 1 includes participants with severe renal impairment who receive a single oral dose of INCB123667, while Group 2 includes participants with end stage renal disease who receive two single oral doses. The study is open-label and randomized, allowing comparison between these two groups to monitor the drugs effects and safety. Participants will be monitored for up to approximately three months, focusing on the drug levels in their blood at different times after dosing. Researchers will also track any treatment-related side effects during this period. The study aims to provide detailed information about the drugs safety and how it behaves in the body in people with serious kidney conditions.
CONDITIONS
Brief Title
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease
Research Team
I
Incyte Corporation Call Center (US)
I
Incyte Corporation Call Center (ex-US)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
